ARCT-810 is under clinical development by Arcturus Therapeutics Holdings and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ARCT-810’s likelihood of approval (LoA) and phase transition for Ornithine-Transcarbamylase Deficiency took place on 07 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ARCT-810 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ARCT-810 overview

ARCT-810 is under development for the treatment of ornithine transcarbamylase (OTC) deficiency. It is administered through the intravenous route. The drug candidate is an ornithine transcarbamylase (OTC) mRNA. It is developed based on lipid-enabled and unlocked nucleic acid modified RNA delivery technology (LUNAR) platform and manufactured by NanoAssemblr technology. It acts by targeting periportal hepatocytes.

Arcturus Therapeutics Holdings overview

Arcturus Therapeutics Holdings (Arcturus) formerly Arcturus Therapeutics Ltd, is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases. The company discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery systems. Arcturu’s pipeline products portfolio include ARCT-810 (LUNAR-OTC), ARCT-032 (LUNAR-CF), ARCT-021 (LUNAR-COV19 Vaccine) and LUNAR Flu. It provides messenger RNA (mRNA), that is used as protein replacement therapy to treat diseases caused by a lack of protein and by defective proteins for cystic fibrosis. The company RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and COVID-19. Arcturus is headquartered in San Diego, California, the US.

Quick View ARCT-810 LOA Data

Report Segments
  • Innovator
Drug Name
  • ARCT-810
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.